Page 2 - Nasdaq Siox News Today

Sio Gene Therapies (NASDAQ:SIOX – Get Rating) and Organigram (NASDAQ:OGI – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends. Insider and Institutional Ownership 11.0% of Organigram shares are […]

NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (Nasdaq:SIOX) today announced that its Board of Directors has determined, after...

Shares of Sio Gene Therapies Inc. (NASDAQ:SIOX – Get Rating) have been assigned a consensus recommendation of “Hold” from the seven research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy […]

Sio Gene Therapies Inc. (NASDAQ:SIOX – Get Rating) was the target of a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 204,700 shares, a drop of 37.2% from the April 30th total of 326,100 shares. Approximately 0.4% of the shares of the stock are […]

-Company Announces Termination of Licensing Agreement for GM1 and GM2 Gene Therapies with the University of Massachusetts-Company has engaged SVB...

Shares of Sio Gene Therapies Inc. (NASDAQ:SIOX – Get Rating) have earned a consensus rating of “Buy” from the seven research firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price […]

Sio Gene Therapies Inc. (NASDAQ:SIOX – Get Rating) was the target of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 703,600 shares, an increase of 26.6% from the February 13th total of 555,800 shares. Based on an average daily volume of 582,300 shares, […]

Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 1/2 trial of AXO-AAV-GM1 for the treatment of GM1...

During the last session, Sio Gene Therapies Inc. (NASDAQ:SIOX)’s traded shares were 0.33 million, with the beta value of the company hitting 1.75. At the end of the trading day, the stock’s price was $2.49, reflecting an intraday gain of 1.63% or $0.04. The 52-week high for the SIOX share is $5.74, that puts it down -130.52 from that peak though still a striking 25.3% gain since the share price plummeted to a 52-week low of $1.86. The company’s market capitalization is $144.27M, and the a...

Sio Gene Therapies, Inc. (NASDAQ:SIOX)’s traded shares stood at 451,895 during the last session, with the company’s beta value hitting 1.7. At the close of trading, the stock’s price was $2.53, to imply an increase of 3.69% or $0.09 in intraday trading. The SIOX share’s 52-week high remains $5.74, putting it -126.88% down since that peak but still an impressive +26.48% since price per share fell to its 52-week low of $1.86. The company has a valuation of $146.2 Million, with an average ...